Freedom Broker initiated coverage of Inogen (INGN) with a Buy rating and $12 price target The firm says Inogen is a respiratory-focused company and home medical equipment provider transitioning from a pure-play portable oxygen concentrator manufacturer into a broader respiratory care platform. The company is entering a phase of improving operating efficiency, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INGN: